Published in Obesity and Diabetes Week, July 18th, 2005
Study 1: Atorvastatin significantly reduced vascular events in high-risk patients with type 2 diabetes.
"Vascular complications are a major cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). The recently published Collaborative Atorvastatin Diabetes Study (CARDS) showed that atorvastatin (10 mg, once daily vs placebo) markedly reduces vascular events in this high-risk population. The participants (n=2,838) were fairly typical T2DM patients without cardiovascular disease and with at least one other risk factor: hypertension,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week